• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估难治性或不明原因慢性咳嗽的咳嗽症状严重程度:来自患者焦点小组和国际专家小组的研究结果

Assessing cough symptom severity in refractory or unexplained chronic cough: findings from patient focus groups and an international expert panel.

作者信息

Kum Elena, Guyatt Gordon H, Munoz Caroline, Beaudin Suzanne, Li Shelly-Anne, Abdulqawi Rayid, Badri Huda, Boulet Louis-Philippe, Chen Ruchong, Dicpinigaitis Peter, Dupont Lieven, Field Stephen K, French Cynthia L, Gibson Peter G, Irwin Richard S, Marsden Paul, McGarvey Lorcan, Smith Jaclyn A, Song Woo-Jung, O'Byrne Paul M, Satia Imran

机构信息

Dept of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.

Dept of Medicine, McMaster University, Hamilton, ON, Canada.

出版信息

ERJ Open Res. 2022 Mar 14;8(1). doi: 10.1183/23120541.00667-2021. eCollection 2022 Jan.

DOI:10.1183/23120541.00667-2021
PMID:35295233
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8918938/
Abstract

BACKGROUND

Cough symptom severity represents an important subjective end-point to assess the impact of therapies for patients with refractory or unexplained chronic cough (RCC/UCC). As existing instruments assessing the severity of cough are neither widely available nor tested for measurement properties, we aim to develop a new patient-reported outcome measure addressing cough severity.

OBJECTIVE

The aim of this study was to establish items and domains that would inform development of a new cough severity instrument.

METHODS

Three focus groups involving 16 adult patients with RCC/UCC provided data that we analysed using directed content analysis. Discussions led to consensus among an international panel of 15 experts on candidate items and domains to assess cough severity.

RESULTS

The patient focus group provided 48 unique items arranged under broad domains of urge-to-cough sensations and cough symptom. Feedback from expert panel members confirmed the appropriateness of items and domains, and provided an additional subdomain related to cough triggers. The final conceptual framework comprised 51 items in the following domains: urge-to-cough sensations (subdomains: frequency and intensity) and cough symptom (subdomains: triggers, control, frequency, fit/bout duration, intensity, quality and associated features/sequelae).

CONCLUSIONS

Consensus findings from patients and international experts established domains of urge-to-cough and cough symptom with associated subdomains and relevant items. The results support item generation and content validity for a novel patient-reported outcome measure for use in health research and clinical practice.

摘要

背景

咳嗽症状严重程度是评估难治性或不明原因慢性咳嗽(RCC/UCC)患者治疗效果的重要主观终点。由于现有的评估咳嗽严重程度的工具既未广泛应用,也未对其测量特性进行测试,我们旨在开发一种新的患者报告结局指标来评估咳嗽严重程度。

目的

本研究的目的是确定可用于开发新的咳嗽严重程度评估工具的条目和领域。

方法

三个焦点小组,共16名成年RCC/UCC患者提供了数据,我们使用定向内容分析法进行分析。讨论促使15名国际专家组成的小组就评估咳嗽严重程度的候选条目和领域达成共识。

结果

患者焦点小组提供了48个独特的条目,这些条目归为咳嗽冲动感觉和咳嗽症状这两个宽泛领域。专家小组成员的反馈证实了条目的适宜性,并提供了一个与咳嗽触发因素相关的新子领域。最终的概念框架包括51个条目,分属以下领域:咳嗽冲动感觉(子领域:频率和强度)和咳嗽症状(子领域:触发因素、控制、频率、发作/持续时间、强度、性质及相关特征/后遗症)。

结论

患者和国际专家达成的共识确定了咳嗽冲动和咳嗽症状的领域以及相关子领域和条目。这些结果支持了一种用于健康研究和临床实践的新型患者报告结局指标的条目生成及内容效度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79d4/8918938/d4c81650141d/00667-2021.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79d4/8918938/09c8b94f1078/00667-2021.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79d4/8918938/d4c81650141d/00667-2021.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79d4/8918938/09c8b94f1078/00667-2021.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79d4/8918938/d4c81650141d/00667-2021.02.jpg

相似文献

1
Assessing cough symptom severity in refractory or unexplained chronic cough: findings from patient focus groups and an international expert panel.评估难治性或不明原因慢性咳嗽的咳嗽症状严重程度:来自患者焦点小组和国际专家小组的研究结果
ERJ Open Res. 2022 Mar 14;8(1). doi: 10.1183/23120541.00667-2021. eCollection 2022 Jan.
2
Cough symptom severity in patients with refractory or unexplained chronic cough: a systematic survey and conceptual framework.难治性或不明原因的慢性咳嗽患者的咳嗽症状严重程度:系统调查和概念框架。
Eur Respir Rev. 2021 Jul 13;30(161). doi: 10.1183/16000617.0104-2021. Print 2021 Sep 30.
3
Content validity of the Leicester Cough Questionnaire in adults with refractory or unexplained chronic cough: a qualitative interview study.莱斯特咳嗽问卷在难治性或不明原因的慢性咳嗽成人中的内容效度:一项定性访谈研究。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241274261. doi: 10.1177/17534666241274261.
4
The Severity of Chronic Cough Diary (SCCD): development and content validation of a novel patient-reported outcome instrument for evaluating the symptom experience of chronic cough.慢性咳嗽日记严重程度表(SCCD):一种评估慢性咳嗽症状体验的新型患者报告结局工具的开发和内容验证。
J Patient Rep Outcomes. 2023 Jul 10;7(1):65. doi: 10.1186/s41687-023-00605-8.
5
The McMaster Cough Severity Questionnaire (MCSQ): a cough severity instrument for patients with refractory chronic cough.麦克马斯特咳嗽严重程度问卷(MCSQ):一种用于难治性慢性咳嗽患者的咳嗽严重程度评估工具。
Eur Respir J. 2025 Feb 6;65(2). doi: 10.1183/13993003.01565-2024. Print 2025 Feb.
6
Quantitative measurement properties and score interpretation of the Cough Severity Diary in patients with chronic cough.慢性咳嗽患者咳嗽严重程度日记的定量测量特性和评分解读。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620915155. doi: 10.1177/1753466620915155.
7
Patient-reported experiences with refractory or unexplained chronic cough: a qualitative analysis.患者对难治性或不明原因的慢性咳嗽的体验:定性分析。
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241236025. doi: 10.1177/17534666241236025.
8
Determining What Represents Value in the Treatment of Refractory or Unexplained Chronic Cough from the Perspective of Key Stakeholders in Spain Using Multi-Criteria Decision Analysis.采用多准则决策分析方法,从西班牙关键利益相关者的角度确定治疗难治性或不明原因慢性咳嗽的价值所在。
Appl Health Econ Health Policy. 2023 Jan;21(1):119-130. doi: 10.1007/s40258-022-00770-9. Epub 2022 Nov 2.
9
Treatment of Unexplained Chronic Cough: CHEST Guideline and Expert Panel Report.不明原因慢性咳嗽的治疗:CHEST指南与专家小组报告
Chest. 2016 Jan;149(1):27-44. doi: 10.1378/chest.15-1496. Epub 2016 Jan 6.
10

引用本文的文献

1
Top 10 priorities for chronic cough: Canadian James Lind Alliance Priority-Setting Partnership (CAN-COUGH).慢性咳嗽的十大优先事项:加拿大詹姆斯·林德联盟优先事项设定合作项目(CAN-COUGH)
ERJ Open Res. 2025 Aug 4;11(4). doi: 10.1183/23120541.01370-2024. eCollection 2025 Jul.
2
Psychometric validation of the severity of chronic cough diary, leicester cough questionnaire, and a cough severity visual analogue scale in patients with refractory chronic cough.慢性咳嗽日记严重程度、莱斯特咳嗽问卷及咳嗽严重程度视觉模拟量表在难治性慢性咳嗽患者中的心理测量学验证
J Patient Rep Outcomes. 2025 Jun 11;9(1):65. doi: 10.1186/s41687-025-00888-z.
3

本文引用的文献

1
Feasibility and clinical utility of ambulatory cough monitoring in an outpatient clinical setting: a real-world retrospective evaluation.门诊临床环境中动态咳嗽监测的可行性及临床应用:一项真实世界回顾性评估
ERJ Open Res. 2021 Oct 4;7(4). doi: 10.1183/23120541.00319-2021. eCollection 2021 Oct.
2
Cough symptom severity in patients with refractory or unexplained chronic cough: a systematic survey and conceptual framework.难治性或不明原因的慢性咳嗽患者的咳嗽症状严重程度:系统调查和概念框架。
Eur Respir Rev. 2021 Jul 13;30(161). doi: 10.1183/16000617.0104-2021. Print 2021 Sep 30.
3
Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.
Recruiting participants for focus groups in health research: a meta-research study.
健康研究中焦点小组参与者的招募:一项元研究
BMC Med Res Methodol. 2025 Jan 14;25(1):9. doi: 10.1186/s12874-025-02464-x.
4
An exploration of clinically meaningful definitions of cough bouts.咳嗽发作临床意义明确的定义探索。
ERJ Open Res. 2024 Dec 2;10(6). doi: 10.1183/23120541.00316-2024. eCollection 2024 Nov.
5
Patient-reported assessments of chronic cough in clinical trials: accessory or primary endpoints?临床试验中患者报告的慢性咳嗽评估:次要终点还是主要终点?
J Thorac Dis. 2024 Oct 31;16(10):7165-7181. doi: 10.21037/jtd-24-705. Epub 2024 Oct 30.
6
The McMaster Cough Severity Questionnaire (MCSQ): a cough severity instrument for patients with refractory chronic cough.麦克马斯特咳嗽严重程度问卷(MCSQ):一种用于难治性慢性咳嗽患者的咳嗽严重程度评估工具。
Eur Respir J. 2025 Feb 6;65(2). doi: 10.1183/13993003.01565-2024. Print 2025 Feb.
7
Exploring the concept of disease control in chronic cough.探索慢性咳嗽疾病控制的概念。
ERJ Open Res. 2024 Sep 30;10(5). doi: 10.1183/23120541.00320-2024. eCollection 2024 Sep.
8
Development and validation of a novel questionnaire to describe and assess sensations and triggers associated with refractory and unexplained chronic cough.开发并验证了一种新的问卷,用于描述和评估与难治性和不明原因的慢性咳嗽相关的感觉和触发因素。
BMJ Open Respir Res. 2024 Aug 13;11(1):e002430. doi: 10.1136/bmjresp-2024-002430.
9
Burden of Disease Associated with Refractory and Unexplained Chronic Cough in Canada: Results from a National Survey.与加拿大难治性和不明原因的慢性咳嗽相关的疾病负担:一项全国性调查的结果。
Lung. 2024 Aug;202(4):415-424. doi: 10.1007/s00408-024-00714-1. Epub 2024 Jun 12.
10
Association of Cough Severity with Asthma Control and Quality of Life in Patients with Severe Asthma.咳嗽严重程度与重度哮喘患者哮喘控制和生活质量的相关性。
Lung. 2024 Aug;202(4):405-414. doi: 10.1007/s00408-024-00710-5. Epub 2024 Jun 7.
依利帕昔单抗(BAY 1817080),一种 P2X3 受体拮抗剂,治疗难治性慢性咳嗽:一项随机、安慰剂对照、交叉 2a 期研究。
Eur Respir J. 2021 Nov 18;58(5). doi: 10.1183/13993003.04240-2020. Print 2021 Nov.
4
Performance of a digital signal processing algorithm for the accurate quantification of cough frequency.一种用于准确量化咳嗽频率的数字信号处理算法的性能
Eur Respir J. 2021 Aug 12;58(2). doi: 10.1183/13993003.04271-2020. Print 2021 Aug.
5
Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.参与 P2X3 受体拮抗剂 Gefapixant 二期临床试验的难治性或不明原因慢性咳嗽患者的特征。
Lung. 2021 Apr;199(2):121-129. doi: 10.1007/s00408-021-00437-7. Epub 2021 Apr 7.
6
Quantitative measurement properties and score interpretation of the Cough Severity Diary in patients with chronic cough.慢性咳嗽患者咳嗽严重程度日记的定量测量特性和评分解读。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620915155. doi: 10.1177/1753466620915155.
7
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.Gefapixant,一种 P2X3 受体拮抗剂,用于治疗难治性或原因不明的慢性咳嗽:一项随机、双盲、对照、平行分组、2b 期试验。
Lancet Respir Med. 2020 Aug;8(8):775-785. doi: 10.1016/S2213-2600(19)30471-0. Epub 2020 Feb 25.
8
Gefapixant in two randomised dose-escalation studies in chronic cough.在两项慢性咳嗽随机剂量递增研究中的gefapixant
Eur Respir J. 2020 Mar 20;55(3). doi: 10.1183/13993003.01615-2019. Print 2020 Mar.
9
BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.BLU-5937:一种选择性 P2X3 拮抗剂,具有强大的镇咳作用且不改变味觉。
Pulm Pharmacol Ther. 2019 Jun;56:56-62. doi: 10.1016/j.pupt.2019.03.007. Epub 2019 Mar 20.
10
The heterogeneity of chronic cough: a case for endotypes of cough hypersensitivity.慢性咳嗽的异质性:咳嗽超敏反应表型的案例。
Lancet Respir Med. 2018 Aug;6(8):636-646. doi: 10.1016/S2213-2600(18)30150-4. Epub 2018 Jun 18.